Medical Products > General Medical > Pleur Evac
Client: Deknatel Division of Pfizer
(Pleur-evac is now sold by Teleflex.
For more information please visit www.teleflex.com or contact 800-367-7874)
drainage is frequently necessary for thoracic, cardiovascular, trauma and critical
care. The original method for chest drainage required the careful and precise
addition of water to regulate the amount of suction placed on the thoracic
Adding water was difficult in an often chaotic setting. In
addition, at the time of DCI's initial participation, the original patents
that protected the Pleur-Evac product line were nearing expiration, and a number
of companies in the medical industry were developing similar devices.
Deknatel needed an upgraded version of the device that would
solve the major problems with the original device and that would also provide
a strong patent position.
DCI conceived of a "dry suction" system that would not require the
addition of water for suction regulation. A wide range of conceptual approaches
was examined to support the new technology, up to and including the preparation
of highly refined proof-of-principal models. DCI worked closely with the Deknatel
technical staff as the concepts demonstrated in the proof-of-principal models
were prepared for manufacture and worldwide distribution.
Over the span of 4 years, the development work performed by DCI resulted in
the assignment of 5 new patents to Pfizer and the emergence of several new
products based on the DCI patents. These innovative products were ultimately
responsible for preserving and/or expanding Deknatel's dominance in this